188 related articles for article (PubMed ID: 24284056)
21. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
[TBL] [Abstract][Full Text] [Related]
22. Apoptosis induced by the methanol extract of Salvia miltiorrhiza Bunge in non-small cell lung cancer through PTEN-mediated inhibition of PI3K/Akt pathway.
Ye YT; Zhong W; Sun P; Wang D; Wang C; Hu LM; Qian JQ
J Ethnopharmacol; 2017 Mar; 200():107-116. PubMed ID: 28088493
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological significance of PTEN and PI3K/AKT signal transduction pathway in non-small cell lung cancer.
Yun F; Jia Y; Li X; Yuan L; Sun Q; Yu H; Shi L; Yuan H
Int J Clin Exp Pathol; 2013; 6(10):2112-20. PubMed ID: 24133589
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFR.
Cetin Z; Ozbilim G; Erdogan A; Luleci G; Karauzum SB
Med Oncol; 2010 Sep; 27(3):853-60. PubMed ID: 19763916
[TBL] [Abstract][Full Text] [Related]
25. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation.
Nunez MI; Behrens C; Woods DM; Lin H; Suraokar M; Kadara H; Hofstetter W; Kalhor N; Lee JJ; Franklin W; Stewart DJ; Wistuba II
J Thorac Oncol; 2012 May; 7(5):833-40. PubMed ID: 22729036
[TBL] [Abstract][Full Text] [Related]
26. [Loss and inactivation of PTEN/MMAC1/TEP1 gene in lung cancer].
Zhang L; Liu T; Liu H; Gao J; Gu C
Zhonghua Bing Li Xue Za Zhi; 2000 Apr; 29(2):85-8. PubMed ID: 11866895
[TBL] [Abstract][Full Text] [Related]
27. [Expression and significance of PTEN/PI3K signal transduction-related proteins in non-small cell lung cancer].
Liao DW; Wang L; Zhang XG; Liu MQ
Ai Zheng; 2006 Oct; 25(10):1238-42. PubMed ID: 17059767
[TBL] [Abstract][Full Text] [Related]
28. c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas.
Tsuta K; Kozu Y; Mimae T; Yoshida A; Kohno T; Sekine I; Tamura T; Asamura H; Furuta K; Tsuda H
J Thorac Oncol; 2012 Feb; 7(2):331-9. PubMed ID: 22198430
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical characterization of the mTOR pathway in stage-I non-small-cell lung carcinoma.
Shin E; Choi CM; Kim HR; Jang SJ; Park YS
Lung Cancer; 2015 Jul; 89(1):13-8. PubMed ID: 25936472
[TBL] [Abstract][Full Text] [Related]
30. Notch Signaling Components: Diverging Prognostic Indicators in Lung Adenocarcinoma.
Liu ZY; Wu T; Li Q; Wang MC; Jing L; Ruan ZP; Yao Y; Nan KJ; Guo H
Medicine (Baltimore); 2016 May; 95(20):e3715. PubMed ID: 27196489
[TBL] [Abstract][Full Text] [Related]
31. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
Micke P; Mattsson JS; Edlund K; Lohr M; Jirström K; Berglund A; Botling J; Rahnenfuehrer J; Marincevic M; Pontén F; Ekman S; Hengstler J; Wöll S; Sahin U; Türeci O
Int J Cancer; 2014 Nov; 135(9):2206-14. PubMed ID: 24710653
[TBL] [Abstract][Full Text] [Related]
32. Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.
Zito CR; Jilaveanu LB; Anagnostou V; Rimm D; Bepler G; Maira SM; Hackl W; Camp R; Kluger HM; Chao HH
PLoS One; 2012; 7(2):e31331. PubMed ID: 22355357
[TBL] [Abstract][Full Text] [Related]
33. Radiation/paclitaxel treatment of p53-abnormal non-small cell lung cancer xenograft tumor and associated mechanism.
Li G; Zhao J; Peng X; Liang J; Deng X; Chen Y
Cancer Biother Radiopharm; 2012 May; 27(4):227-33. PubMed ID: 22489661
[TBL] [Abstract][Full Text] [Related]
34. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.
Tang JM; He QY; Guo RX; Chang XJ
Lung Cancer; 2006 Feb; 51(2):181-91. PubMed ID: 16324768
[TBL] [Abstract][Full Text] [Related]
35. Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase.
Scrima M; De Marco C; Fabiani F; Franco R; Pirozzi G; Rocco G; Ravo M; Weisz A; Zoppoli P; Ceccarelli M; Botti G; Malanga D; Viglietto G
PLoS One; 2012; 7(2):e30427. PubMed ID: 22363436
[TBL] [Abstract][Full Text] [Related]
36. Correlation of epithelial-mesenchymal transition markers with clinicopathologic parameters in adenocarcinomas and squamous cell carcinoma of the lung.
Kim SH; Kim JM; Shin MH; Kim CW; Huang SM; Kang DW; Suh KS; Yi ES; Kim KH
Histol Histopathol; 2012 May; 27(5):581-91. PubMed ID: 22419022
[TBL] [Abstract][Full Text] [Related]
37. Ubiquitin specific peptidase 49 inhibits non-small cell lung cancer cell growth by suppressing PI3K/AKT signaling.
Shen WM; Yin JN; Xu RJ; Xu DF; Zheng SY
Kaohsiung J Med Sci; 2019 Jul; 35(7):401-407. PubMed ID: 31001918
[TBL] [Abstract][Full Text] [Related]
38. Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients.
Sterlacci W; Fiegl M; Hilbe W; Jamnig H; Oberaigner W; Schmid T; Augustin F; Auberger J; Obermann EC; Tzankov A
J Thorac Oncol; 2010 Sep; 5(9):1325-36. PubMed ID: 20631637
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3Cβ(D1067V) kinase domain mutation.
Pazarentzos E; Giannikopoulos P; Hrustanovic G; St John J; Olivas VR; Gubens MA; Balassanian R; Weissman J; Polkinghorn W; Bivona TG
Oncogene; 2016 Mar; 35(9):1198-205. PubMed ID: 25982275
[TBL] [Abstract][Full Text] [Related]
40. Increased BCAR1 predicts poor outcomes of non-small cell lung cancer in multiple-center patients.
Deng B; Sun Z; Jason W; Yang P
Ann Surg Oncol; 2013 Dec; 20 Suppl 3(0 3):S701-8. PubMed ID: 23904007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
